山东大学教师主页窦蕾 Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China Home

Home > Scientific Research > Paper Publications

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China

Release Time:2023-10-08 Hits:

Institution:卫生管理与政策研究中心
Journal:Frontiers in Immunology
First Author:刘世贤
Document Code:1A62E71633BF49E4821F0B68962B4011
Issue:14
Number of Words:4
Translation or Not:No
Date of Publication:2023-05

Prev One:Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China

Next One:Psychometric properties and comparison of four health utility approaches among myopia patients in China

Home

Scientific Research

Teaching Research

Awards and Honours

Enrollment Information

Student Information

My Album

Blog

Personal Information

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China